β-blockade: Benefits beyond blood pressure reduction?

Journal of Clinical Hypertension

Volumn 14, Issue 2, 2012, Pages 112-120

  Cockcroft, John R ^a   Pedersen, Michala E ^b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; C REACTIVE PROTEIN; CELIPROLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LEPTIN; METOPROLOL; NEBIVOLOL; NITRIC OXIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEONECTIN; OSTEOPONTIN; OSTEOPROTEGERIN; PINDOLOL; PRACTOLOL; PROPRANOLOL; STEROID; TUMOR NECROSIS FACTOR ALPHA;

AGE; ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; AUGMENTATION INDEX; BETA ADRENERGIC RECEPTOR BLOCKING; BODY MASS; BONE DENSITY; BONE FRAGILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC HEART FAILURE; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FRAGILITY FRACTURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERTENSION; LEUKOCYTE; META ANALYSIS (TOPIC); NONHUMAN; OSTEOBLAST; OSTEOPOROSIS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; REVIEW; RISK REDUCTION; SIDE EFFECT; SMOKING; SYSTOLIC HEART FAILURE; SYSTOLIC HYPERTENSION; VASODILATATION; VERTEBRA FRACTURE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BENZOPYRANS; BLOOD PRESSURE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COMORBIDITY; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; HUMANS; OSTEOPOROSIS; PERIPHERAL ARTERIAL DISEASE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VASCULAR STIFFNESS; VASODILATOR AGENTS;

EID: 84856291770     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2011.00553.x     Document Type: Review

References (137)

1. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114:2871-2891.
2. Dzau VJ, Antman EM, Black HR, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006;114:2850-2870.
3. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2:8-11.
4. Kado DM, Browner WS, Blackwell T, et al. Rate of bone loss is associated with mortality in older women: a prospective study. J Bone Miner Res. 2000;15:1974-1980.
5. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
6. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008;121(suppl 1):S9-S14.
7. Frishman WH. Β-Adrenergic blockers: a 50-year historical perspective. Am J Ther. 2008;15:565-576.
8. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.
10. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
11. Wiysonge CS, Bradley H, Mayosi BM, et al. Β-blockers for hypertension. Cochrane Database Syst Rev. 2007;1:CD002003.
12. Bangalore S, Sawhney S, Messerli FH. Relation of β-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008;52:1482-1489.
13. Pedersen ME, Cockcroft JR. The vasodilatory β-blockers. Curr Hypertens Rep. 2007;9:269-277.
14. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther. 1995;274:1067-1071.
15. Dessy C, Saliez J, Ghisdal P, et al. Endothelial β3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation. 2005;112:1198-1205.
16. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121(suppl 5):121S-126S.
17. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007;370:741-750.
18. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-532.
19. Lopez AD, Mathers CD, Ezzati M, et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367:1747-1757.
20. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31:204-212.
21. Hole DJ, Watt GC, Davey-Smith G, et al. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711-715; discussion 715-716.
22. Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet. 2000;356:1313-1317.
23. Schunemann HJ, Dorn J, Grant BJ, et al. Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. Chest. 2000;118:656-664.
24. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev Respir Dis. 1989;2:S49-S55.
25. Tockman MS, Pearson JD, Fleg JL, Fleg JL Rapid decline in FEV1. A new risk factor for coronary heart disease mortality. Am J Respir Crit Care Med. 1995;1:390-398.
26. Finkelstein J, Cha E, Scharf SM. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-349.
27. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259-1265.
28. Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574-580.
29. Barr RG, Mesia-Vela S, Austin JH, et al. Impaired flow-mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007;176:1200-1207.
30. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588-2605.
31. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318-1327.
32. Bolton CE, Cockcroft JR, Sabit R, et al. Lung function in mid-life compared with later life is a stronger predictor of arterial stiffness in men: the Caerphilly Prospective Study. Int J Epidemiol. 2009;38:867-876.
33. Jankowich MD, Taveira T, Wu WC. Decreased lung function is associated with increased arterial stiffness as measured by peripheral pulse pressure: data from NHANES III. Am J Hypertens. 2010;23:614-619.
34. Bolton CE, Cockcroft JR. Lung function and cardiovascular risk: a stiff challenge? Am J Hypertens. 2010;23:584.
35. Rutten FH, Cramer MJ, Grobbee DE, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26:1887-1894.
36. Cheriyan J, Wilkinson IB. Role of increased aortic stiffness in the pathogenesis of heart failure. Curr Heart Fail Rep. 2007;4:121-126.
37. Sabit R, Bolton CE, Fraser AG, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104:1171-1178.
38. Padeletti M, Jelic S, LeJemtel TH. Coexistent chronic obstructive pulmonary disease and heart failure in the elderly. Int J Cardiol. 2008;125:209-215.
39. Sin DD, Man SF. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease Circulation. 2003;107:1514-1519.
40. Sesso HD, Buring JE, Rifai N, et al. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-2951.
41. Schillaci G, Pirro M, Gemelli F, et al. Increased C-reactive protein concentrations in never-treated hypertension: the role of systolic and pulse pressures. J Hypertens. 2003;21:1841-1846.
42. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003;108:2993-2999.
43. Thorleifsson SJ, Margretardottir OB, Gudmundsson G, et al. Chronic airflow obstruction and markers of systemic inflammation: results from the BOLD study in Iceland. Respir Med. 2009;103:1548-1553.
44. Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest 2006;130:326-333.
45. Man SF, Connett JE, Anthonisen NR, et al. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax. 2006;61:849-853.
46. Margretardottir OB, Thorleifsson SJ, Gudmundsson G, et al. Hypertension, systemic inflammation and body weight in relation to lung function impairment-an epidemiological study. COPD. 2009;6:250-255.
47. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007;370:797-799.
48. Coulson JM, Rudd JH, Duckers JM, et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18F-FDG PET pilot study. J Nucl Med. 2010;51:1357-1360.
49. Sabit R, Shale DJ. Vascular structure and function in chronic obstructive pulmonary disease: a chicken and egg issue? Am J Respir Crit Care Med. 2007;176:1175-1176.
50. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32:962-969.
51. Mills NL, Miller JJ, Anand A, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008;63:306-311.
52. Cockcroft JR. Exploring vascular benefits of endothelium-derived nitric oxide. Am J Hypertens. 2005;2:177S-183S.
53. Eickhoff P, Valipour A, Kiss D, et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;178:1211-1218.
54. Moro L, Pedone C, Scarlata S, et al. Endothelial dysfunction in chronic obstructive pulmonary disease. Angiology. 2008;59:357-364.
55. Ashrafian H, Violaris AG. Β-blocker therapy of cardiovascular diseases in patients with bronchial asthma or COPD: the pro viewpoint. Prim Care Respir J. 2005;14:236-241.
56. Salpeter S, Ormiston T, Salpeter E. Cardioselective β-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.
57. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens. 2006;8(suppl 12):40-52.
58. Lee TA, Pickard AS, Au DH, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149:380-390.
59. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness by measuring pulse wave velocity: a systematic review. Curr Vasc Pharmacol. 2010;8:638-644.
60. Takami T, Shigemasa M. Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients. Hypertens Res. 2003;26:609-614.
61. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554-2560.
62. Münzel T, Gori T. Nebivolol: the somewhat-different β-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491-1499.
63. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem. 2007;4:129-136.
64. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation. 2005;112:3795-3801.
65. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation. 2001;104:511-514.
66. McEniery CM, Schmitt M, Qasem A, et al. Nebivolol increases arterial distensibility in vivo. Hypertension. 2004;44:305-310.
67. Dal Negro R. Pulmonary effects of nebivolol. Ther Adv Cardiovasc Dis. 2009;3:329-334.
68. Cazzola M, Matera MG, Ruggeri P, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration. 2004;71:159-164.
69. Iakushin SS, Okorokov VG, Liferov RA, et al. [Assessment of safety and antihypertensive efficacy of a cardioselective β-blocker nebivolol in patients with hypertension and concomitant chronic obstructive bronchitis]. Kardiologiia. 2002;42:36-39.
70. Matthys H, Giebelhaus V, Von Fallois J. [Nebivolol (nebilet) a β blocker of the third generation - also for patients with obstructive lung diseases?]. Z Kardiol. 2001;90:760-765.
71. Kotlyar E, Keogh AM, Macdonald PS, et al. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290-1295.
72. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between β-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-1787.
73. Au DH, Bryson CL, Fan VS, et al. Β-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004;117:925-931.
74. Rutten FH, Zuithoff NP, Hak E, et al. Β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
75. Short PM, Lipworth SI, Elder DH, et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011;342:d2549.
76. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53-67.
77. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:926-934.
78. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Osteoporosis Review. Bethesda, MD: National Institute of Arthritis and Musculoskeletal and Skin Diseases; 2010.
79. Compston J. Osteoporosis: social and economic impact. Radiol Clin North Am. 2010;48:477-482.
80. Cappuccio FP, Meilahn E, Zmuda JM, Cauley JA. High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of Osteoporotic Fractures Research Group. Lancet. 1999;354:971-975.
81. Farhat GN, Newman AB, Sutton-Tyrrell K, et al. The association of bone mineral density measures with incident cardiovascular disease in older adults. Osteoporos Int. 2007;18:999-1008.
82. Tanko LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int. 2003;73:15-20.
83. Choi SH, An JH, Lim S, et al. Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women. Clin Endocrinol (Oxf). 2009;71:644-651.
84. Mikumo M, Okano H, Yoshikata R, et al. Association between lumbar bone mineral density and vascular stiffness as assessed by pulse wave velocity in postmenopausal women. J Bone Miner Metab. 2009;27:89-94.
85. Blaha MJ, Budoff MJ, Rivera JJ, et al. Relationship of carotid distensibility and thoracic aorta calcification: multi-ethnic study of atherosclerosis. Hypertension. 2009;54:1408-1415.
86. McEniery CM, McDonnell BJ, So A, et al. Aortic calcification is associated with aortic stiffness and isolated systolic hypertension in healthy individuals. Hypertension. 2009;53:524-531.
87. Hjortnaes J, Butcher J, Figueiredo JL, et al. Arterial and aortic valve calcification inversely correlates with osteoporotic bone remodelling: a role for inflammation. Eur Heart J. 2010;31:1975-1984.
88. Bagger YZ, Tanko LB, Alexandersen P, et al. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med. 2006;259:598-605.
89. Kim SH, Kim YM, Cho MA, et al. Echogenic carotid artery plaques are associated with vertebral fractures in postmenopausal women with low bone mass. Calcif Tissue Int. 2008;82:411-417.
90. Watson KE, Bostrom K, Ravindranath R, et al. TGF-β 1 and 25-hydroxycholesterol stimulate osteoblast-like vascular cells to calcify. J Clin Invest. 1994;93:2106-2113.
91. Parhami F, Bostrom K, Watson K, Demer LL. Role of molecular regulation in vascular calcification. J Atheroscler Thromb. 1996;3:90-94.
92. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2001;21:1998-2003.
93. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
94. Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650-655.
95. Ding C, Parameswaran V, Udayan R, et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93:1952-1958.
96. Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010;54:123-132.
97. Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136:1456-1465.
98. Evans DM, Ralston SH. Nitric oxide and bone. J Bone Miner Res. 1996;11:300-305.
99. Wimalawansa S, Chapa T, Fang L, et al. Frequency-dependent effect of nitric oxide donor nitroglycerin on bone. J Bone Miner Res. 2000;15:1119-1125.
100. Wimalawansa SJ. Nitric oxide and bone. Ann N Y Acad Sci. 2010;1192:391-403.
101. Ducy P, Amling M, Takeda S, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell. 2000;100:197-207.
102. Elefteriou F, Ahn JD, Takeda S, et al. Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature. 2005;434:514-520.
103. Takeda S, Elefteriou F, Levasseur R, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell. 2002;111:305-317.
104. Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol. 2006;33:720-724.
105. Samuels A, Perry MJ, Gibson RL, et al. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone. 2001;29:24-29.
106. Dogru MT, Aydos TR, Aktuna Z, et al. The effects of β-blockers on endothelial nitric oxide synthase immunoreactivity in the rat corpus cavernosum. Urology. 2010;75:589-597.
107. Fu GS, Huang H, Chen F, et al. Carvedilol ameliorates endothelial dysfunction in streptozotocin-induced diabetic rats. Eur J Pharmacol. 2007;567:223-230.
108. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of β-blockers and risk of fractures. JAMA. 2004;292:1326-1332.
109. Wiens M, Etminan M, Gill SS, et al. Effects of antihypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med. 2006;260:350-362.
110. Yang S, Nguyen ND, Center JR, et al. Association between β-blocker use and fracture risk: the Dubbo Osteoporosis Epidemiology Study. Bone. 2011;48:451-455.
111. Cepeda MS. The use of propensity scores in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2000;9:103-104.
112. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327-333.
113. Amoh-Tonto CA, Malik AR, Kondragunta V, et al. Brachial-ankle pulse wave velocity is associated with walking distance in patients referred for peripheral arterial disease evaluation. Atherosclerosis. 2009;206:173-178.
114. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
115. Cheng KS, Tiwari A, Baker CR, et al. Impaired carotid and femoral viscoelastic properties and elevated intima-media thickness in peripheral vascular disease. Atherosclerosis. 2002;164:113-120.
116. Tai NR, Giudiceandrea A, Salacinski HJ, et al. In vivo femoropopliteal arterial wall compliance in subjects with and without lower limb vascular disease. J Vasc Surg. 1999;30:936-945.
117. Mitchell GF, Vita JA, Larson MG, et al. Cross-sectional relations of peripheral microvascular function, cardiovascular disease risk factors, and aortic stiffness: the Framingham Heart Study. Circulation 2005;112:3722-3728.
118. Safar ME. Arterial stiffness and peripheral arterial disease. Adv Cardiol. 2007;44:199-211.
119. Cooke JP, Wilson AM. Biomarkers of peripheral arterial disease. J Am Coll Cardiol. 2010;55:2117-2123.
120. De Haro J, Acin F, Lopez-Quintana A, et al. Direct association between C-reactive protein serum levels and endothelial dysfunction in patients with claudication. Eur J Vasc Endovasc Surg. 2008;35:480-486.
121. De Haro J, Acin F, Medina FJ, et al. Relationship between the plasma concentration of C-reactive protein and severity of peripheral arterial disease. Clin Med Cardiol. 2009;3:1-7.
122. Khawaja FJ, Kullo IJ. Novel markers of peripheral arterial disease. Vasc Med. 2009;14:381-392.
123. Cambou JP, Aboyans V, Constans J, et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg. 2010;39:577-585.
124. Sleszycka J, Wozniak K, Banaszek M, et al. [Prevalence and difficulties in chronic obstructive pulmonary disease diagnosis in patients suffering from severe peripheral arterial disease]. Pol Merkur Lekarski. 2009;27:92-96.
125. De Lucas-Ramos P, Izquierdo-Alonso JL, Rodriguez-Gonzalez Moro JM, et al. [Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study]. Arch Bronconeumol. 2008;44:233-238.
126. Castagna O, Boussuges A, Nussbaum E, et al. Peripheral arterial disease: an underestimated aetiology of exercise intolerance in chronic obstructive pulmonary disease patients. Eur J Cardiovasc Prev Rehabil. 2008;15:270-277.
127. Mangiafico RA, Russo E, Riccobene S, et al. Increased prevalence of peripheral arterial disease in osteoporotic postmenopausal women. J Bone Miner Metab. 2006;24:125-131.
128. Safar ME, Priollet P, Luizy F, et al. Peripheral arterial disease and isolated systolic hypertension: the ATTEST study. J Hum Hypertens. 2009;23:182-187.
129. Ostchega Y, Paulose-Ram R, Dillon CF, et al. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55:583-589.
130. Paravastu SC, Mendonca D, Da Silva A. Β blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2008;(4):CD005508.
131. Cazzola M, Bettoncelli G, Sessa E, et al. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration. 2010;80:112-119.
132. Carbone L, Buzkova P, Fink HA, et al. Hip fractures and heart failure: findings from the Cardiovascular Health Study. Eur Heart J. 2010;31:77-84.
133. Winkel TA, Hoeks SE, Schouten O, et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the REduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg. 2010;40:9-16.
134. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-225.
135. Ashley C, Burton D, Sverrisdottir YB, et al. Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia. J Physiol. 2010;588:701-712.
136. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J. 2006;28:219-242.
137. Basu S, Michaelsson K, Olofsson H, et al. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun. 2001;288:275-279.